Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Novo Nordisk buys insulin company Ziylo for potentially more than $800 million

by Ryan Cross
August 24, 2018 | A version of this story appeared in Volume 96, Issue 34

 

Novo Nordisk will purchase the British diabetes drug maker Ziylo in a deal that could earn Ziylo more than $800 million. The University of Bristol spin-off has created molecules that bind glucose. Nordisk may use them to create glucose-responsive insulin therapies, which could reduce the risk of hypoglycemia in diabetics. Nordisk may also find a use for Ziylo’s molecules in glucose-monitoring devices. Separately, Nordisk will work with the German company Evotec to develop small-molecule drugs for diabetes, obesity, and related conditions, including the liver disease nonalcoholic steatohepatitis.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.